Neurogene INC. (NGNE) — 10-K Filings
All 10-K filings from Neurogene INC.. Browse 2 Annual Report reports with AI-powered summaries and risk analysis.
10-K Filings (2)
-
Neurogene's Losses Mount Amid NGN-401 Trial Progress
— Mar 24, 2026 Risk: high
Neurogene Inc. (NGNE) reported a net loss of $90.4 million for the fiscal year ended December 31, 2025, an increase from $75.1 million in 2024, bringing its acc -
Neurogene Inc. Files 2024 10-K
— Mar 24, 2025 Risk: medium
Neurogene Inc. filed its 2024 10-K on March 24, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly known as Neoleukin Therapeuti
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX